Skip to main content

Latest Articles

Latest Articles

Showing 9 / 872 Weight Management articles

Soha Ali Khan Praises Aishwarya Mohanraj's Mounjaro Use for Weight Loss Amid ...
GLP-1 Medications

Soha Ali Khan Praises Aishwarya Mohanraj's Mounjaro Use for Weight Loss Amid ...

In a refreshing moment of candor amid the Ozempic debate, Bollywood actress Soha Ali Khan has praised influencer Aishwarya Mohanraj for admitting her use of Mounjaro for weight loss. This celebrity endorsement underscores growing openness about GLP-1 medications in entertainment circles. Discover the science behind these drugs and their implications for metabolic health.

Shotlee··5 min read
Amazon Pharmacy Expands Same-Day Delivery to 4,500 US Cities
Pharmacy Services

Amazon Pharmacy Expands Same-Day Delivery to 4,500 US Cities

Amazon Pharmacy is set to revolutionize prescription access by expanding same-day delivery to about 4,500 US cities and towns by the end of 2024, reaching nearly 2,000 new communities. This includes states like Idaho and Massachusetts, building on partnerships for GLP-1 obesity treatments with WeightWatchers. Patients managing metabolic health conditions can expect quicker delivery of essential medications.

Shotlee··5 min read
Meijer Reduces Out-of-Pocket Costs for GLP-1 Meds Like Ozempic, Wegovy
Pharmacy Savings & GLP-1 Medications

Meijer Reduces Out-of-Pocket Costs for GLP-1 Meds Like Ozempic, Wegovy

Meijer is making GLP-1 medications more affordable by accepting manufacturer savings programs for Ozempic and Wegovy, dropping costs to $199 per month for the first two months on lowest doses. The retailer also offers the newly approved oral Wegovy through the same program, starting at $149 out-of-pocket. This move aims to boost access to these popular weight loss injections amid rising demand.

Shotlee··5 min read
Novo Nordisk Sues Hims & Hers Over Semaglutide Patent
GLP-1 Regulatory News

Novo Nordisk Sues Hims & Hers Over Semaglutide Patent

Novo Nordisk has filed a lawsuit against Hims & Hers Health Inc., accusing the telehealth company of breaching its U.S. patent on semaglutide used in blockbuster obesity drugs like Ozempic and Wegovy. Despite Hims scrapping plans for a copycat Wegovy pill, Novo claims the compounded versions remain dangerous and infringing. This legal battle highlights growing tensions over compounded GLP-1 drugs post-shortage.

Shotlee··5 min read